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Background: Vitamin D deficiency is associated with multiple adverse health outcomes including increased
morbidity and mortality in the general population and in critically ill patients. However, no randomized controlled
trial has evaluated so far whether treatment with sufficiently large doses of vitamin D can improve clinical outcome
of patients in an intensive care setting.
Methods/design: The VITdAL@ICU trial is an investigator-initiated, non-commercial, double-blind,
placebo-controlled randomized clinical trial. This study compares high-dose oral cholecalciferol (vitamin D3) versus
placebo treatment in a mixed population of 480 critically ill patients with low 25-hydroxyvitamin-D levels at study
enrollment (≤ 20ng/ml). Following an initial loading dose of 540,000 IU of vitamin D3, patients receive 90,000 IU of
vitamin D3 on a monthly basis for 5 months. The study is designed to compare clinical outcome in the two study
arms with the primary endpoint being length of hospital stay. Secondary endpoints include among others length
of ICU stay, the percentage of patients with 25(OH)D levels > 30 ng/ml at day 7, ICU and hospital mortality and
duration of mechanical ventilation. We describe here the VITdAL@ICU study protocol for the primary report.
Discussion: This trial is designed to evaluate whether high-dose vitamin D3 is able to improve morbidity and
mortality in a mixed population of adult critically ill patients and correct vitamin D deficiency safely.
Trial registration: ClinicalTrials: NCT01130181
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Vitamin D is a key regulator in calcium and phosphorus
metabolism and likely confers physiologically relevant
pleiotropic functions that include cardioprotective and
immunomodulatory effects as well as improvement of
antimicrobial action [1-6]. Profound vitamin D deficiency
in humans causes rickets in children or osteomalacia in
adults together with vitamin D myopathy, whereas low
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reproduction in any medium, provided the orprevalence of a multitude of other diseases [1,6] includ-
ing an increase in mortality [7,8].
Moreover, a systematic review concluded that inter-
vention with cholecalciferol significantly reduced mortal-
ity in predominantly elderly, institutionalized women [9].
To date, only few large interventional randomized trials
have investigated the effect of vitamin D on clinical out-
comes. The rationale for pleiotropic effects of this sub-
stance is based on the fact that the vitamin D receptor
(VDR) is almost ubiquitously expressed, and the vast
majority of cells respond to 1,25(OH)2D exposure. Hun-
dreds of genes with vitamin D receptor response ele-
ments directly or indirectly influence cell cycling, cell
proliferation, differentiation and apoptosis [6,10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Endogenous synthesis in the presence of UV-B radiation
is the main source of vitamin D. Therefore, immobilized
and elderly individuals are prone to develop vitamin D
deficiency. Low vitamin D levels are highly prevalent in
critically ill adults and children [11-18]. Unfortunately,
no uniform definition of vitamin D deficiency exists and
tissue levels of the major active metabolite 1,25(OH)2D
are currently not measurable. Today most guidelines
agree, however, that a “low” vitamin D status is present
when serum 25(OH)D levels are below 20 ng/ml [1,19].
Special concerns in the ICU setting relate to the issue as
to whether the definition of vitamin D deficiency should
be the same as in the general population or whether spe-
cial metabolites of vitamin D should be considered in
this definition as well [20]. Insufficient vitamin D levels
could affect this population in various ways [21]. Over
the last years, several groups have reported on an in-
verse association between vitamin D levels in critically
ill patients and severity of disease including length of
ICU stay and mortality [13,14,16,22,23]. Moreover, vita-
min D levels decline further during ICU stay [24]
which is explained by insufficient replacement of vita-
min D via enteral or parenteral nutrition in the ab-
sence of UV-B exposure. To date, only few and small
intervention studies (n=22-33 patients) that were not
designed to demonstrate effects on clinical outcomes
have been published [12,25-27].
Vitamin D and proposed clinical effects pertinent to the
critically ill patient
Calcium homeostasis and bone turnover
In critically ill patients, hypocalcemia is frequently
present and has been related to increased morbidity and
mortality [28-30]. Reasons for hypocalcemia are not well
understood, but besides elevated levels of IL-6, vitamin
D deficiency may play a decisive role [31-34]. Without
correction of vitamin D deficiency, calcium levels may
be impossible to normalize [29]. To maintain serum cal-
cium levels, parathyroid hormone levels rise and induce
accelerated bone resorption which is aggravated by pro-
longed immobilization ultimately resulting in significant
bone loss. Interestingly, even relatively low doses of
intravenous vitamin D (500 IU daily) might be able to at-
tenuate this detrimental physiological response [12].
Cardiovascular system
The heart is an important target organ for vitamin D,
both on a genomic and nongenomic level [35]. Cardio-
myocytes express the VDR. Severe hypocalcemia may
cause life-threatening, reversible heart failure [36].
Vitamin D seems to inhibit activation of the renin-
angiotensin system as well as the expression of genes
involved in the development of myocardial hypertrophy[37]. There is accumulating evidence that vitamin D
deficiency may be an important factor in the develop-
ment of congestive heart failure and sudden cardiac
death [38]. In chronic hemodialysis patients, calcitriol
supplementation is associated with reduction of cardiac
hypertrophy and a reduction of QT dispersion [39], the
latter being considered a major risk factor for
arrhythmia and sudden cardiac death.
Our group found a negative correlation of 25(OH)D
with NT-pro-BNP levels, NYHA functional classes and
impaired left ventricular function [38]. Hazard ratios for
death attributable to heart failure and sudden cardiac
death were 2.8 and 5.0, respectively, when patients with
severe vitamin D deficiency (25(OH)D <10 ng/ml) were
compared with those considered having optimal serum
levels (25(OH)D >30 ng/ml) [38]. The anti-inflammatory
properties of vitamin D may play an additional role in
congestive heart failure [40]. In animal models, vitamin
D deficiency is associated with myocardial hypertrophy
and fibrosis leading to aberrant cardiac contractility and
relaxation [41,42]. Moreover, calcitriol treatment was
able to prevent cardiac hypertrophy under in-vitro con-
ditions or in VDR knock-out animals [41,42].Immune system/sepsis/inflammation
Vitamin D acts on both the adaptive and innate im-
munity systems. Most cells of the immune system ex-
press the VDR [6]. It enables macrophages to respond to
and kill bacterial and viral organisms. In line with this is
the observation of impaired macrophage function in
VDR knock-out mice [6]. Vitamin D also exerts an influ-
ence on epidermal keratinocytes to fulfill their barrier
function [43]. Monocytes cultured in severely vitamin D-
deficient plasma express less cathelicidines and improve
their function with 25(OH)D as well as 1,25(OH)2D
[44]. Cathelicidines are important antimicrobial peptides
that are of great interest in critically ill patients because
they constitute part of the initial defense line against
pathogens. They are expressed in epithelia of airways,
the bladder and gastrointestinal tract, which are all
considered important entry sites of nosocomial infec-
tions. Treatment of normal human bronchial epithelial
cells with 1,25(OH)2D results in a 10-fold up-regulation
of cathelicidin mRNA levels after 12 hours [45]. In septic
ICU patients, a positive correlation between circulating
25(OH)D and LL-37 levels, the active fragment of cathe-
licidin, has been reported [46]. In a large retrospective
study, the risk for blood culture positivity was signifi-
cantly higher in vitamin D deficient critically ill patients
[13]. Of interest in this context is also the finding that
sepsis incidence and case-fatality rates are significantly
higher in winter despite similarities in disease severity
during summer time [47].
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Severe vitamin D deficiency is associated with myopathy,
decreased muscle strength and an increased risk for falls
[1]. In intensive care, this may translate to the necessity
of prolonged mechanical ventilation and difficulties dur-
ing remobilization and weaning from ventilatory support
in patients with low vitamin D status. In randomized
controlled trials, vitamin D supplementation improved
muscle strength in elderly patients [48] and decreased
the frequency of falls [48-50].
Guidelines and practices
For the general population, the Institute of Medicine
(IOM) recommends a daily allowance for adults of 600 to
800 IU [51], while the Endocrine Society Guideline
recommends 1,500–2,000 IU of vitamin D3 per day for
the at-risk population [52]. Upper daily limits for adults
are 4,000 (IOM)–10,000 (Endocrine Society) IU per day.
Guidelines for parenteral nutrition recommend 200
IU per day and typical enteral nutrition formulas con-
tain 200–300 IU of ergocalciferol or cholecalciferol
per 1000 ml. Available over the counter multivitamin
preparations commonly contain 200 IU of vitamin D2
or D3. Currently, there is no intravenous vitamin D-
monopreparation available, although high-dose intra-
muscular preparations may be an option in selected
patients.
Rationale of the study and hypothesis
In summary, vitamin D plays a pivotal role in calcium
homeostasis and is, based on current knowledge, asso-
ciated with disease severity and mortality in critically ill
patients. Moreover, vitamin D exhibits a number of
pleiotropic effects that are of special interest to the ICU
patient [20,53,54] However, so far it is unclear whether a
low vitamin D status is causally linked to adverse out-
comes or merely an epiphenomenon reflecting poor
health status. In contrast to previous clinical trials that
failed to show a benefit for correcting hormonal insuffi-
ciencies in critical illness (e.g. administration of growth
hormone or steroids) [55,56], one has to bear in mind
that vitamin D not only acts on endocrine, but also auto-
crine level which allows for tissue-specific control of
1,25(OH)2D regulation and action that may be com-
pletely independent of circulating calcitriol levels. As far
as we know now vitamin D also has an excellent safety
profile with a broad therapeutic window [19,57].
The hypothesis of this first large RCT is that supple-
mentation with a sufficiently large dose of vitamin D
leads to a fast correction of low vitamin D status and
possibly to clinical benefits, particularly relating to im-
mune, cardiac and muscle function. Because these po-
tential benefits likely occur at various functional
hierarchies, we chose “length of hospital stay” as aprimary surrogate marker for a change in morbidity in
this patient group.
Results from the pilot study relevant for the design of
this trial
To optimize study design and ascertain safety and effi-
cacy of the chosen loading dose of 540,000 IU of cho-
lecalciferol, we performed a pilot trial in 25 medical
critically ill patients with vitamin D deficiency [25]. Ad-
verse effects like hypercalcemia or hypercalciuria did not
occur in this pilot study and vitamin D levels increased
significantly in most patients within two days, although
2 out of 10 patients showed no or only a modest rise in
25(OH)D levels at day 7. We therefore chose to continue
with the same loading dose, but added monthly main-
tenance doses of vitamin D to the study protocol.
Justification of high-dose vitamin D3 intervention
The half-life of 25(OH)D following oral cholecalciferol
supplementation allows the administration of large
doses. In elderly patients with vitamin D deficiency and
healthy individuals, large loading doses rapidly and safely
normalized 25(OH)D levels [58-60]. However, an annual
high-dose intervention was associated with a higher risk
of falls and fractures in elderly patients [61]. Some con-
traindications such as sarcoidosis and other granulo-
matous diseases also need to be considered before
administration of a high loading dose [62,63]. Following
publication of the detrimental effects of a high-dose vita-
min D intervention on the risk of falls and fractures
[61], we decided to nevertheless proceed with the initial
study protocol because in our population, a rapid restor-
ation of vitamin D status may still have positive effects
on patient immunity and even muscular function. We
are aware that smaller doses of vitamin D3 are likely an
effective treatment option for most patients with low
vitamin D status within months but this time span may
be too long during critical illness.
Methods/design
Study design
The VITdAL@ICU trial is an investigator-initiated, non-
commercial, double-blind, placebo-controlled rando-
mized clinical trial. This study compares high-dose oral
cholecalciferol (vitamin D3) versus placebo treatment in
a mixed population of 480 critically ill patients with low
25(OH)D levels at study enrollment (≤ 20ng/ml). Follow-
ing an initial loading dose of 540,000 IU of vitamin D3,
patients receive 90,000 IU of vitamin D3 on a monthly
basis for 5 months resulting in a total treatment/-
observation period of 6 months. The VITdAL@ICU
study is conducted at the Medical University of Graz,
Austria, a tertiary care university hospital with a catch-
ment area covering the Southeast of Austria (population
Amrein et al. BMC Endocrine Disorders 2012, 12:27 Page 4 of 9
http://www.biomedcentral.com/1472-6823/12/27approximately 1.5 million). It recruits patients from five
ICUs: medical (15 beds), neurological (8 beds), cardiothor-
acic surgery (13 beds) and two mixed surgery units (12
and 10 beds, respectively).
Eligibility criteria for inclusion and recruitment
Upon admission to one of the five participating ICUs, all
adult patients undergo screening for study participation.
Patients ≥18 years who are expected to stay at the ICU
≥48 hours and are vitamin D deficient (25(OH)D level ≤
20 ng/ml) are screened for inclusion and exclusion cri-
teria. The following patients are not considered eligible
for inclusion: patients expected to die within the upcom-
ing 24 hours, with severely impaired gastrointestinal mo-
tility (ileus, gastric volume > 400 ml), contraindication
for study drug application (orally or via feeding tube),
readmission after participation in the VITdAL@ICU
pilot study, enrolment in another intervention trial or
documented hypercalcemia (total calcium >2.65 or
ionized serum calcium >1.35 mmol/l). Patients with aDay 2-7 
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unable to take study medication; 
DNR/imminent death; hypercalcemia; 
nephrolithiasis, tuberculosis or 
sarcoidosis; pregnancy/lactation; other 
ongoing trial; consent refusal 
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Figure 1 Trial procedures flow sheet.history of granulomatous disease (tuberculosis, sarcoid-
osis), recent kidney stones (≤ 1 year) as well as pregnant
or lactating women are also excluded from this trial. An
overview of the study procedures is given in Figure 1.
Ethical aspects and informed consent
The institutional ethical committee of the Medical Uni-
versity of Graz, Austria (reference number 21–214 ex
09/10, EudraCT-Nr.: 2010-018798-39), and the Austrian
Agency for Health and Food Safety (AGES) approved
the study. Informed consent is obtained prior to inclu-
sion into the study according to the Austrian law. The
patient can withdraw from the study at any time, with-
out giving any reason and without impact on treatment.
A register is kept of all patients evaluated for inclusion
and of patients who choose to withdraw from the study.
Randomization
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to one of the two treatment study groups, “Vitamin D”Assigned to placebo 
(oleum arachidis) 
Blood and urine draw 
ion/exclusion criteria 
 (25(OH)D<20ng/ml) 
 > 18yrs 
U stay > 48h 
Informed Consent  
Inclusion 
ndomization stratified by ICU and gender 
) 
F (i.e. antibiotics, insulin…) 
rine draws on day 3 and 7 
f study medication for home use 
ine draw at day 28 if feasible 
orresponding placebo monthly 
eck for study medication intake and vital status 
ariants 
e 
ding blood/urine sample, clinical examination 
tiometry 
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randomization tool “Randomizer for Clinical Trials”
(www.randomizer.at). Block randomization is used with
patients stratified according to ICU and gender.Study drug preparation, labeling and intake
The cholecalciferol preparation is provided by Fresenius
Kabi, Austria. As placebo, oleum arachidis is used. Iden-
tical bottles of study medication containing 180,000 IU
of cholecalciferol in 15 ml of oleum arachidis or corre-
sponding placebo are prepared and labeled at the institu-
tional pharmacy. Study medication is stored at room
temperature. For usage of the study medication outside
of the ICU, the patient, next of kin or continuing care-
giver/s are instructed by the study team and receive oral
and written information on how and when to take the
remaining study medication. Furthermore, they are
asked to refrain from additional use of vitamin D over
the following 6 months. Additionally, the patient’s family
practitioner and, if applicable, treating general ward or
rehabilitation facility are personally informed or con-
tacted by telephone and instructed about the study.Interventions
“Vitamin D”: Patients randomized to the “Vitamin D”
group receive a loading dose of 540,000 IU of vitamin
D3 orally or via feeding tube. This dose equals three bot-
tles of a commercially available vitamin D preparation in
Austria: Oleovit D3W solution; concentration of chole-
calciferol is 400 IU vitamin D3/drop of oleum arachidis.
Total carrier volume is 45 ml. From month 1 to 5,
patients receive monthly maintenance doses of 90,000
IU cholecalciferol.
“Placebo”: Patients randomized to the “Placebo” group
receive oleum arachidis in the same volume and time
schedule as “Vitamin D” patients.Routine low-dose vitamin D supplementation in both
study arms during ICU stay
Patients in both study arms are allowed to receive regu-
lar low dose (approximately 200 IU per day) vitamin D
supplements via enteral and/or parenteral nutrition as
deemed appropriate by the treating physicians during
stay at the ICU, but are not allowed to receive any vita-
min D preparations during their stay at the general ward
or at home.Handling of readmissions to ICU
Patients who are readmitted to intensive care after par-
ticipation in the VITdAL@ICU trial are not eligible for
reinclusion.Blinding of treatment allocation
All persons involved in patient care of the RCT are
blinded to treatment allocation and all study-related ac-
tivities are carried out in a double-blind fashion.
Primary outcome measures
The primary efficacy endpoint for this RCT is the length
of stay (LOS) in the hospital starting from application of
the study medication. The end is defined as the time of
hospital discharge or death of the patient. Further
admissions to rehabilitation facilities are not taken into
account. Before unblinding all relevant facilities are inde-
pendently classified by two study team members.
Secondary outcome measures
Secondary endpoints for this RCT include:
 length of ICU stay starting from application of study
medication
 ICU and hospital mortality, 28-day mortality,
6-month mortality
 percentage of patients with 25(OH)D levels ≥ 30 ng/
ml at day 7
 duration of mechanical ventilation including CPAP/
mask ventilation starting from application of study
medication
 need for a tracheostomy during ICU stay
 surrogate markers for cardiac function: need for
vasopressor therapy during ICU stay, and duration
of such need, NT-proBNP levels
 analysis of biochemical and endocrine variables
relevant to calcium- and phosphorus metabolism;
1,25(OH)D and PTH at days 0,3,7, 28 and
month 6
 C-Reactive Protein and procalcitonin levels
 clinical parameters at 6 months (falls, Timed Up &
Go – test, hand grip strength, lumbar and hip BMD,
Quality of life and performance status, number of
hospitalizations, number of respiratory tract
infections)
 serum cathelicidin levels at day 0 and 7 are planned
to be analyzed from frozen samples and will be
reported separately
Data collected at study entry
At baseline, data on demographic and clinical character-
istics of the patients are obtained. Simplified Acute
Physiology Score (SAPS II), presence of comorbidities,
medical history, admission diagnosis by category and
relevant medication are registered.
The following categories for diagnosis at admission
and concomitant diagnoses are predefined:
 Surgical ICU admissions:
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surgery, brain surgery, transplantation, other
surgical reasons
 Medical or neurological ICU admissions:
 cardiovascular, respiratory, hematological/
oncological, sepsis/infectious, gastrointestinal/
hepatic, renal, metabolic, neurological, other
non-surgical reasons
In addition, we record the need for and the number of
days of hemodynamic support and mechanical ventila-
tion including noninvasive ventilation and tracheostomy
as well as the quantity and formula of enteral/parenteral
nutrition given. Information on insulin requirements
and use of antibiotics are registered on day 0, 2 and 6.
Blood and urinary samples
Venous blood samples are taken upon ICU admission
and in the morning on days 0,3,7,28 if feasible. Analyses
include routine serum chemistry, hematology, markers
of inflammation and parameters of calcium and vitamin
D metabolism. Additional measurements of markers of
metabolism and inflammation as well as other endocrine
parameters are planned on stored samples that are fro-
zen and stored at −70°C.
25(OH)D assay
25(OH)D serum levels are measured by ELISA (Immu-
nodiagnostic Systems, Boldon, UK).
Reminder calls and follow-up procedures
All patients who leave the hospital are contacted by tele-
phone on a monthly basis to check for compliance with
the monthly intake of the study drug (5 times) and vital
status.The long-term follow-up appointment at 6 and 24
months is performed in two ways, dependent on the
patient’s mobility and preference:
 Variant A (estimated 80%): Follow-up visit by
telephone
 Variant B (estimated 20%): Visit at the clinic,
including additional: Blood and urinary testing (similar to that on days
0,3,7,28)
 Timed Up & Go – Test (in seconds)
 Hand grip strength (in mmHg)
 Dual X-ray absorptiometry (DXA) with bone
mineral density (at the hip and the lumbar spine)
and body compositionThe following data set is collected in all patients: Compliance with intake of study drug (number of
maintenance doses)
 Additional vitamin D intake
 Falls and fractures since study inclusion (number)
 Respiratory tract infections (number and use of
antibiotics)
 Hospitalizations (number and cause)
 Performance status (Eastern Cooperative Oncology
Group (ECOG) Score)
 Quality of life
Data management
Data is manually transferred from source files into
paper-based primary CRFs identified by ascending pa-
tient numbers specific to respective ICUs. Data are then
checked for accuracy and transferred to an electronic
CRF by the clinical research assistance team. Extensive
verification checks are performed by a study monitor.
Vital status at 6 months is recorded for all patients.
Safety assessment
Blinded safety assessment for 28-day mortality is
planned after 100 and 240 patients. In case there is a
safety concern, a standby data safety monitoring board
meeting is planned.
Sample size calculation
The sample size was calculated to detect a difference in
mean length of hospital stay of 2 days with 80% power
and a significance level of 5%. Using the Mann–Whitney
U-Test for sample size calculation, a group size of 234 is
needed to show a reduction of 2 days (equivalent to
14%) of the primary study outcome based on a mean
hospital stay of 14 days and standard deviation of 7 days
for the control group. To consider drop-outs of the
study, a sample of 480 patients (240 per arm) was con-
sidered appropriate.
Statistical analyses
The primary analysis for comparing length of hospital
stay between the two groups will be made using the
Mann–Whitney U-test. For secondary endpoints, differ-
ences between the two groups will be evaluated with the
t test or Mann–Whitney U-test for continuous variables
as appropriate and for categorical variables with the chi-
square or Fisher Exact test. Survival endpoints will be
displayed in Kaplan-Meier plots and compared by the
log rank test. Furthermore, linear and logistic regression
models will be applied to adjust for age, disease severity
and 25(OH)D.
A CONSORT diagram will be reported (Figure 2).
Analyses will be performed both on intention to treat
and per protocol population with the intention-to-treat
population as the primary. To assess compliance with
Analyzed (n) 
Lost to follow up (n) 
Assessed for eligibility (n) 
(adult admissions to one of the 5 ICU's) 
Excluded (n) 
 ICU <48h 
 25(OH)D >20ng/ml 
 study medikation intake not 
possible 
 DNR orders/imminent death 
 hypercalcemia 
 … 
Underwent randomization (n) 
Assigned to vitamin D (n) Assigned to placebo (n) 
 Received intervention (n) 
 Discontinued intervention (n) 
 Withdrew or withheld 
consent (n) 
 Consented to data 
analysis, but no 
further study drug 
intake (n) 
 Received intervention (n) 
 Discontinued intervention (n) 
 Withdrew or withheld 
consent (n) 
 Consented to data 
analysis, but no 
further study drug 
intake (n) 
Lost to follow up (n) 
Analyzed (n) 
Figure 2 CONSORT flow diagram. All adult patients admitted to five intensive care units (ICU; medical, neurological, cardiac surgery and two
mixed surgery units) from May 4, 2010 onward were eligible for inclusion.
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ance doses will be reported.Safety endpoints
Safety endpoints comprise vital status (ICU and hospital
mortality, 28-day mortality, 6-month mortality) as well
as serum 25(OH)D and calcium levels. 25(OH)D and
serum calcium levels are measured at day 0, 3, 7 and, if
available, at day 28 and month 6 in order to identify vita-
min D intoxication and/or hypercalcemia. Following the
report by Sanders et al. of a higher risk of falls and frac-
tures in elderly women on an annual high-dose vitamin
D regime in May 2010 [61], we decided to add the num-
ber of self-reported falls as additional safety endpoint.Discussion
The study has been initiated as planned on May 04
2010. Blinded safety analyses for 28-day mortality after
100 and 240 patients did not reveal a difference between
the two study groups.This study is the first large RCT evaluating the role of
vitamin D on clinical outcomes in critically ill patients.
Therefore, a significant difference in the safety and/or ef-
ficacy endpoints will provide important evidence for or
against the use of high-dose vitamin D intervention in
an intensive care setting and, in the event of a favorable
outcome in the intervention group, aid in the design of
future larger RCTs adequately powered to detect a pos-
sible difference in mortality in ICU patients and possibly
hospitalized patients in general.
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